Orthostatic Hypotension News and Research

RSS
Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

Research examines effects of orthostatic hypotension in adults, children

Research examines effects of orthostatic hypotension in adults, children

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Findings from Study 305 evaluating the effect of Northera reported

Findings from Study 305 evaluating the effect of Northera reported

Chelsea Therapeutics announces financial results for fourth quarter 2009

Chelsea Therapeutics announces financial results for fourth quarter 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

FDA approve Fanapt tablets (iloperidone) to treat adults with schizophrenia

FDA approve Fanapt tablets (iloperidone) to treat adults with schizophrenia

Seroquel XR supplemental NDA recommended for approval

Seroquel XR supplemental NDA recommended for approval

FDA approves Symbyax for treatment-resistant depression

FDA approves Symbyax for treatment-resistant depression

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms